Charles Gregory Vontz joins BioPharmX board of directors
Mr. Vontz most recently served as president and CEO of Topica Pharmaceuticals, which developed luliconazole for fungal infections of the skin, a product acquired by Medicis Pharmaceutical Corporation.
Earlier, Mr. Vontz was president and chief operating officer of Connetics Corporation, a public specialty pharmaceutical company, focusing on dermatology. Connetics was acquired by Stiefel Pharmaceuticals in late 2006.
Before joining Connetics, Mr. Vontz spent 12 years at Genentech in various senior marketing and product development roles.
He got his start in the pharmaceutical industry with Merck, Sharp and Dohme where he worked from 1985-1987 in sales and sales management.
Mr. Vontz is also a member of the board of directors for SinuSys Corporation.
He is a graduate of the University of Florida and received a Masters in Business Administration from the Haas School of Business at the University of California at Berkeley. ■
LATEST MOVES FROM California
- Depomed appoints Santosh J. Vetticaden as CSO
- Wells Fargo names Michael Roemer as chief compliance officer
- ARMO BioSciences appoints Joseph Leveque as CMO
- Amyris appoints Eduardo Alvarez as COO
- ChromaDex appoints Kevin Farr as CFO
More inside POST
Big Lots Q2 income $29.1 million Earnings
Ambarella Q2 2018 revenue u 10% Earnings